HCC1143細(xì)胞

ATCC Number： CRL-2321?

相關(guān)**： 導(dǎo)管癌

細(xì)胞形態(tài)： 上皮樣

是否是腫瘤細(xì)胞： 1

物種來(lái)源： 人

組織來(lái)源： duct

生長(zhǎng)狀態(tài)： 貼壁生長(zhǎng)

運(yùn)輸方式： 凍存運(yùn)輸

器官來(lái)源： **

年限： TNM stage IIA, grade 3

數(shù)量： 大量

Designations: HCC1143

Depositors: AF Gazdar, AK Virmani

HCC1143細(xì)胞Biosafety Level: 1

Shipped: frozen

Medium & Serum: See Propagation

Growth Properties: adherent

Organism: Homo sapiens

Morphology: epithelial

Source: Organ: mammary gland; breast

Tissue: duct

Tumor Stage: TNM stage IIA, grade 3

Disease: primary ductal carcinoma

Cellular Products: Epithelial glycoprotein 2 [EGP2]; cytokeratin 19

Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.

Restrictions: The line is available with the following restrictions: 1. This cell line was deposited at the ATCC by Dr. Adi F. Gazdar and is provided for research purposes only. HCC1143細(xì)胞Neither the cell line nor products derived from it may be sold or used for commercial purposes. Nor can the cells be distributed to third parties for purposes of sale, or producing for sale, cells or their products. The cells are provided as service to the research community. They are provided without warranty of merchantability or fitness for a particular purpose or any other warranty, expressed or implied. 2. Any proposed commercial use of the these cells, or their products must first be negotiated with the University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd., Dallas, Texas 75235. Telephone (214) 648-1888, Email TechnologyDevelopment@UTSouthwestern.edu, or Fax: (214) 951-0935.

Isolation: Isolation date: August 30, 1994

Applications: HCC1143 was derived from an invasive ductal carcinoma with no lymph node metastases.

The cells are negative for expression of Her2-neu but positive for expression of p53.

HCC1143 is a poorly differentiated cell line that was initiated on August 30, 1994; it took 29 months to establish.

HCC1143 is positive for the epithelial cell specific marker Epithelial Glycoprotein 2 and for cytokeratin 19, and is negative for expression of estrogen receptor (ER) and progesterone receptor (PR).

Oncogene: her2/neu -; p53 +

DNA Profile (STR): Amelogenin: X

CSF1PO: 10

D13S317: 12

D16S539: 11,13

D5S818: 11

D7S820: 12

THO1: 9.3

TPOX: 12

vWA: 16

HCC1143細(xì)胞Cytogenetic Analysis: polyploid

Age: 52 years *****

Gender: female

Ethnicity: Caucasian

Comments: HCC1143 is a poorly differentiated cell line that was initiated on August 30, 1994; it took 29 months to establish.

HCC1143 was derived from an invasive ductal carcinoma with no lymph node metastases.

The cells are negative for expression of Her2-neu but positive for expression of p53.

HCC1143 is positive for the epithelial cell specific marker Epithelial Glycoprotein 2 and for cytokeratin 19, and is negative for expression of estrogen receptor (ER) and progesterone receptor (PR).

Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.

Temperature: 37.0°C

Subculturing: Protocol: Remove medium, rinse with 0.25% trypsin, 0.53 mM EDTA solution, add an additional 1 to 2 ml of trypsin solution and allow the flask to set at room temperature (or incubate at 37C) until cells detach. Add fresh culture medium, aspirate and dispense into new culture flasks.

Subcultivation Ratio: A subcultivation ratio of 1:2 to 1:4 is recommended

Medium Renewal: Every 3 to 4 days

Preservation: Freeze medium: Complete growth medium, 95%; DMSO, 5%

Storage temperature: liquid nitrogen vapor phase

Related Products: HCC1143細(xì)胞Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001

recommended serum:ATCC 30-2020

normal (or near-normal) cell line established from the same patient:ATCC CRL-2362

purified DNA:ATCC CRL-2321D

purified RNA:ATCC CRL-2321R

References: 38266: Gazdar AF, et al. Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer. Int. J. Cancer 78: 766-774, 1998. PubMed: 9833771